评估多参数磁共振成像在疑似前列腺癌年轻男性中的临床价值
该回顾性研究纳入两个转诊中心2013至2018年间930例接受前列腺MRI及后续活检的患者,评估MRI靶向活检与系统随机活检在不同年龄患者中检测临床显著前列腺癌的差异。结果显示,约50岁以下男性系统随机活检检出率高于MRI靶向活检(40岁时25% vs 16%),50岁以上则MRI靶向活检更高(80岁时48% vs 68%)。
要点
- 年龄是MRI靶向活检检出临床显著前列腺癌的独立预测因素(OR 1.05)。
- 约50岁以下男性,系统随机活检检出率高于MRI靶向活检。
- 50岁以上男性,MRI靶向活检检出率高于系统随机活检。
核心结论
- MRI及MRI靶向活检检测临床显著前列腺癌的表现随患者年龄变化。
- 年轻患者中系统随机活检检出率高于MRI靶向活检,反映MRI在年轻男性中准确性较低。
- 老年患者中MRI靶向活检较系统随机活检有临床获益,检出率更高,提示MRI准确性随年龄增加而提高。
研究设计与样本
- 回顾性识别两个转诊中心2013至2018年间930例接受前列腺MRI及后续活检的患者。
- MRI报告采用前列腺影像报告和数据系统(PI-RADS)。
- MRI检出PI-RADS评分≥3的病灶时,在同一次操作中行MRI靶向活检加系统随机活检。
主要发现
- 总体临床显著前列腺癌率为54%(n=506)。
- 系统随机活检和MRI靶向活检分别有325例(35%)和461例(50%)患者检出临床显著前列腺癌。
- 系统随机活检和MRI靶向活检的中位针数分别为12(四分位距[IQR]:10-13)和5(IQR:4-7)。
- 多变量分析中,校正混杂因素后,活检时年龄仅为MRI靶向活检检出临床显著前列腺癌的独立预测因素(比值比:1.05)。
- 约50岁以下男性中,40岁时系统随机活检检出临床显著前列腺癌的概率高于MRI靶向活检(25% vs 16%);50岁以上男性中MRI靶向活检概率更高,80岁时差异最大(48% vs 68%)。
关键数值与推荐
- 临床显著前列腺癌定义为Gleason评分≥3+4的前列腺癌。
- MRI靶向活检的指征为MRI检出PI-RADS评分≥3的病灶。
局限性
- 主要局限性为回顾性设计。
- 年轻患者数量少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a lack of evidence on the ability of magnetic resonance imaging (MRI) of the prostate to detect clinically significant prostate cancer (csPCa) in young patients. OBJECTIVE: We hypothesised that the diagnostic performance of MRI for csPCa varies according to patient's age. To address this, we assessed the variation in the csPCa detection rate of MRI targeted biopsy (MRI-TBx) versus systematic random biopsy (SBx) across different patient ages. DESIGN, SETTING, AND PARTICIPANTS: We retrospectively identified 930 patients who underwent prostate MRI and subsequent biopsy at two referral centres between 2013 and 2018. The Prostate Imaging Reporting and Data System (PI-RADS) was used for MRI reporting. INTERVENTION: A lesion with a PI-RADS score of ≥3 detected at MRI received an MRI-TBx in addition to an SBx during the same session. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The outcome of our study was the relationship between age and csPCa detection rate at MRI-TBx and SBx, respectively. Clinically significant prostate cancer (PCa) was defined as the presence of PCa with Gleason score ≥3+4. Multivariable logistic regression analyses (MVAs) predicting csPCa detection were assessed for both MRI-TBx and SBx. Covariates were age, prostate-specific antigen density, PI-RADS score, previous biopsy status, digital rectal examination, and the number of targeted and systematic cores. The hypothesis that MRI accuracy in detecting csPCa differed by age was finally tested with a nonparametric loess analysis. RESULTS AND LIMITATIONS: The overall rate of csPCa was 54% (n=506). Overall, 325 (35%) and 461 (50%) patients had csPCa at SBx and MRI-TBx, respectively. The median numbers of SBx and MRI-TBx cores were 12 (interquartile range [IQR]: 10-13) and 5 (IQR: 4-7), respectively. At MVA, age at biopsy was an independent predictor of csPCa at MRI-TBx only (odds ratio: 1.05), after accounting for confounders. In men aged less than roughly 50yr, SBx had a higher probability of detecting csPCa relative to MRI-TBx (25% vs 16% at 40yr). Conversely, in patients aged >50yr, the probability of csPCa was higher in MRI-TBx than in SBx, reaching the highest difference for very elderly patients (48% vs 68% at 80yr). The main limitations were the retrospective design and the small number of young patients. CONCLUSIONS: In this study, we reported the performance of MRI and MRI-TBx in detecting csPCa changes according to patients' age. PATIENT SUMMARY: In young patients, the performance of a systematic random biopsy in detecting clinically significant prostate cancer (csPCa) is higher relative to magnetic resonance imaging targeted biopsy (MRI-TBx), reflecting the lower accuracy of MRI in younger men. Conversely, in older patients, MRI-TBx showed a clinical benefit with a higher csPCa detection rate compared with SBx, suggesting an increase of MRI accuracy with the increase of age.
引用
- Stabile A, Dell'Oglio P, Soligo M, et al. Assessing the Clinical Value of Positive Multiparametric Magnetic Resonance Imaging in Young Men with a Suspicion of Prostate Cancer. Eur Urol Oncol. 2019. PMID: 31204312. doi:10.1016/j.euo.2019.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。